Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1996;44(5):366-71.
doi: 10.1007/BF02602781.

Analysis of anchor residues in a naturally processed HLA-DR53 ligand

Affiliations
Comparative Study

Analysis of anchor residues in a naturally processed HLA-DR53 ligand

H Kobayashi et al. Immunogenetics. 1996.

Abstract

The peptide motif of the HLA-DR53 (DRB4(*)0101) molecule, which is associated with autoimmune diseases including Vogt-Koyanagi-Harada's syndrome, was determined by peptide binding assay using human L plastin p581 - 595 peptide and its substituted analogues. L plastin p581 - 595 peptide is one of the naturally processed peptides bound to HLA-DR9/DR53 (DRB1(*)0901/DRB4(*)0101) molecules. The binding affinity of each peptide to the HLA-DR53 molecule was measured by fluorescence intensity of biotinylated peptides to L cell transfectants expressing HLA-DR53 molecules, followed by treatment with avidin-fluorescence. Binding of biotinylated peptides to HLA-DR53 molecules was not inhibited by all single-alanine-substituted nonbiotinylated peptides, indicating that the replaced position was important for binding to the HLA-DR53 moleule. The inhibitory motif is considered to be an HLA-DR53-specific binding motif, composed of a positively charged residue (K) at position 1, a hydrophobic residue (I) at position 4, positively charged residue (R or K) at position 8 or 9, and another hydrophobic residue (I) at position 10. This predicted motif is different from the binding motifs of other HLA-DR molecules.

PubMed Disclaimer

References

    1. J Immunol. 1993 Jan 15;150(2):499-507 - PubMed
    1. J Immunol. 1991 Aug 15;147(4):1292-8 - PubMed
    1. EMBO J. 1989 Dec 20;8(13):4049-52 - PubMed
    1. Nature. 1993 Jul 1;364(6432):33-9 - PubMed
    1. Immunogenetics. 1995;42(4):299-301 - PubMed

Publication types

MeSH terms